Kornimate/medical-research-clean huggingface dataset:
human alcohol seeking despite aversion

Conditions: Alcohol Abuse

Summary: prolonged alcohol use results in drinking despite resultant problems and adverse consequences. the investigators propose to test a laboratory model of human seeking despite aversion to use as an early marker of disease onset, and as a tool for study of its neural functional substrates, and identification of effective treatments.

the long-term goal for this project is to establish a model of alcohol seeking despite aversion (sda) as a platform for the laboratory testing of novel pharmacologic and behavioral interventions that can be used among those with the highest risk, but who have yet to progress to treatment-resistant drinking. the objective of this application is to test sda across multiple levels of analysis. the investigators consider sda as an early marker of alcohol use disorder progression that is related to lifetime drinking history, alcohol use disorder risks, and brain physiology. the investigators have completed a pilot study demonstrating that sda can be objectively quantified via an intravenous alcohol self-administration task, in which operant work for identical incremental alcohol rewards is paired with aversive stimuli. this preliminary data supports the central hypotheses that behavior in the sda model is attributable to lifetime alcohol exposure, is related to alcohol use disorder risk factors and phenotypes, and reflects alterations in neural system function. in this project, sda will be measured along with recent and lifetime drinking history, negative affect-based rash action (i.e. negative urgency, including action with respect to alcohol use), and self-rating of the effects of alcohol. the rationale for this work is that it would lead to the first objective, well-validated measure of sda in humans.

Eligibility criteria:
inclusion criteria: * healthy men and women age 21-55 * range of lifetime alcohol drinking history from 25 kg to 500 kg, with preference for extremes, plus recent drinking at least 7 drinks/week (women) and 20 drinks/week (men) * able to understand and complete questionnaires and procedures in english * willing and able to tolerate iv placement * right-handed (for fmri arm only) exclusion criteria: * pregnant or breast-feeding * seeking or in treatment for substance use disorder or under court ordered abstinence * medications, medical disorders or conditions that could affect study outcome or subject safety * positive urine drug screen for amphetamines/methamphetamines, barbiturates, benzodiazepines, cocaine, opiates, or phencyclidine * positive breath alcohol (brac) reading on arrival at any study visit * actively suicidal (within previous year) * left-handed or ambidextrous (for fmri arm only)
cost-effectiveness of laser doppler imaging in burn care

Conditions: Burns

Summary: accurate early burn depth assessment is important to determine the optimal treatment. the most applied method to asses burn depth is clinical assessment. this method is the least expensive, but not very accurate. laser doppler imaging (ldi) has been shown to accurately assess burn depth. the clinical effects, the costs and cost-effectiveness of this device however, are unknown. the hypothesis is that an eary accurate diagnosis will lead to an earlier therapeutic decision: surgery or no surgery. earlier excision and grafting probably leads to a decrease in wound healing time, in length of hospital stay and in costs. before the investigators decide to implement ldi in dutch burn care a study of the clinical effects and cost-effectiveness of ldi is necessary. therefore a multicenter randomized controlled trial will be conducted, including all patients with burns of indeterminate depth (burns that are not obviously superficial or full thickness) treated in the dutch burn centres. in total 200 patients will be included in an 18 months period. the patients are randomly divided in two groups: 'new diagnostic strategy' versus 'current diagnostic strategy'. burn depth will be diagnosed both by clinical assessment and laser doppler imaging in all patients. the results of the ldi-scan will be provided to the treating clinician in the 'new diagnostic strategy' group only. time to wound healing, diagnostic and therapeutic decisions, and costs are observed.


Eligibility criteria:
inclusion criteria: * patients with acute burns of indeterminate depth (=intermediate depth, not obviously superficial or full thickness) at presentation * outpatient treatment or admission in one of the three dutch burn centres * presentation within 5 days post burn exclusion criteria * a presence of both burns of indeterminate depth and full thickness at presentation * patients with peri-orbital facial burns, in which the eyes are unable to shield * patients or their next of kin if they are under aged or temporary incompetent who can not be expected to give informed consent e.g. because of cognitive dysfunction or poor dutch proficiency. * patients with a tbsa burned \> 20%

Keywords: burn depth diagnosis laser doppler imaging
decreased empathy and emotion recognition in patients with neurodegenerative disease

Conditions: Neuro-Degenerative Disease; Dementia; Caregiver Burnout; Alzheimer Disease; Frontotemporal Lobar Degeneration; Parkinson Disease; Vascular Dementia

Summary: this study evaluates an educational brochure tailored to caregivers of people with alzheimer's disease, parkinson's disease dementia, lewy body disease, frontotemporal dementia, and vascular disease dementia. the goal of the brochure is educating caregivers about the decreased ability to detect emotion and decreased empathy that can be seen in dementia, increasing caregiver competence in providing care, and teaching caregivers ways to manage over time that lessens burden and improves quality of life.

the 1.5-hour initial visit will involve the caregiver completing questionnaires, structured interviews, and a computer task, and the person with dementia completing a computer task. a 20-30 minute follow-up phone call with the caregiver one month after the initial visit will involve completing questionnaires.

Eligibility criteria:
inclusion criteria: * all caregivers who visit the uhn memory clinic with a patient with a neurodegenerative disease will be asked to participate. * the patient must be aged 50 to 95 (inclusive) and speak english * the caregiver must be aged 30 to 95 (inclusive) and speak english. * the patients must have a diagnosis of one of the following conditions: alzheimer's disease, parkinson's disease/dementia with lewy body, frontotemporal lobar degeneration-syndromes or vascular dementia. * the patient must have a montreal cognitive assessment (moca) score of 10-25 exclusion criteria: * not english speaking. * patients who do not have a caregiver that would be able to participate in the study. * caregivers who do not have a patient being followed at the uhn memory clinic
chronic obstructive pulmonary disease markers and prognosis

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the study aim is to verify the association between the changes in markers of disease and patient´s prognosis in chronic obstructive pulmonary disease.

in a previous study, 133 copd patients were followed-up during the period of one-year. analyses of the association between baseline characteristic and the occurence of disease exacerbation was performed. in this study, the patients included in the previous research will be contacted and invited to participate in a complete evaluation after a three-year period. the association of the changes in dyspnea perception, spirometry variables, body composition, quality of life and exercise tolerance measures with disease prognostic will be studied.

Eligibility criteria:
inclusion criteria: * copd diagnosis according to the gold criteria exclusion criteria: * asthma * inability to perform pulmonary function and exercise tolerance tests * recent myocardial infarction or unstable angina * congestive heart failure: class iii/iv

Keywords: copd survival exacerbation disease markers
quercetin in the prevention of covid-19 infection

Conditions: Covid19

Summary: quercetin is a flavonol, a subclass of flavonoid compounds. of the flavonol molecules, quercetin is the most abundant in fruit and vegetables. quercetin flavonol is characterized by 3 crucial properties: antioxidant, anti-inflammatory and immunomodulatory. the combination of these 3 properties makes quercetin an excellent candidate for dealing with situations in which oxidative stress, inflammation and the immune system are involved. the purpose of the study is to evaluate the effectiveness of an oral nutritional supplement based on quercetin in the prevention of covid-19 infection.


Eligibility criteria:
inclusion criteria: * absence of covid-19 infection exclusion criteria: * previous sars-cov-2 infection demonstrated with antibody positivity through venous sampling * demonstrated presence of sars-cov-2 through a nasopharyngeal antigenic swab before the start of oral nutritional supplementation
the effectiveness of multimodal educational intervention to improve adherence to treatment regimens in older stroke patients

Conditions: Stroke; Medication Adherence; Older Adults

Summary: stroke is a major cause of morbidity and mortality, especially in low and middle income countries including iran. patients with recent stroke or tia are at high risk for new vascular events. several evidence based strategies in secondary prevention of stroke are available but frequently underused. the study is aimed to evaluate an intervention to improve patients with stroke.


Eligibility criteria:
inclusion criteria: * aged 65 years or older * able to give informed consent exclusion criteria: * recurrent stroke * a diagnosis of subarachnoid haemorrhage * significant impairments precluding participation - inability to give informed consent * another condition likely to impact their participation in the trial (e.g. life-threatening condition other than cardiovascular disease) * expected discharge to hospital/nursing home setting
long-term efficacy and safety of lamazym for the treatment of patients with alpha-mannosidosis

Conditions: Alpha-Mannosidosis

Summary: the overall objective is to evaluate the long-term efficacy, safety and tolerability of repeated lamazym i.v. treatment in patients 5-21 years of age with alpha-mannosidosis


Eligibility criteria:
inclusion criteria: * the subject must have participated in the phase 1 trial (eudract number: 2010-022084-36) and phase 2a trial (eudract number: 2010-022085-26) * subject or subjects legally authorized guardian(s) must provide signed, informed consent prior to performing any trial-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject) * the subject and his/her guardian(s) must have the ability to comply with the protocol exclusion criteria: * the subject cannot walk without support * presence of known chromosomal abnormality and syndromes affecting psychomotor development, other than alpha-mannosidosis * history of bone marrow transplantation * presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical conditions that, in the opinion of the investigator, would preclude participation in the trial * any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator, would preclude participation in the trial. * pregnancy: before the start of the treatment the investigators will decide whether or not there is a need for contraception. this assessment will be done through interviews with the patient and parents. the evaluation will be done continuously during the study * psychosis within the last 3 months * planned major surgery that, in the opinion of the investigator, would preclude participation in the trial * participation in other interventional trials testing imp except for studies with lamazym
methadone versus intrathecal hydromorphone for postoperative pain relief in gynecologic cancer undergoing surgery

Conditions: Malignant Female Reproductive System Neoplasm

Summary: this phase iv trial compares methadone versus hydromorphone given in the fluid-filled space between the thin layers of tissue that cover the brain and spinal cord (intrathecal) for postoperative pain relief in patients with gynecologic cancer undergo surgery. methadone binds to opioid receptors in the central nervous system and is a long-acting opioid pain medication. intrathecal hydromorphone works by changing the way the brain and nervous system respond to pain and is similar to an epidural. this trial may help researchers determine if methadone works as well as intrathecal hydromorphone for pain relief after surgery in patients with gynecologic cancer.

primary objective: i. to determine whether intravenous methadone can provide comparable analgesia to an intrathecal injection of hydromorphone. outline: patients are randomized to 1 of 2 arms. arm i: patients receive methadone intravenously (iv) during induction of general anesthesia for standard of care (soc) surgery. arm ii: patients receive hydromorphone intrathecally (it) prior to induction of general anesthesia for soc surgery. after completion of study intervention, patients are followed up at 1 month.

Eligibility criteria:
inclusion criteria: * undergoing surgery with a laparotomy for gynecologic malignancy * planned inpatient admission greater than 24 hours exclusion criteria: * chronic pain requiring greater than 20 morphine milligram equivalents of opioid medications as an outpatient * prolonged corrected qt interval (qtc) \> 500ms * chronic kidney disease with estimated glomerular filtration rate (egfr) \< 30 milliliters per minute (ml/min) * documented cirrhosis * preoperative platelets (plt) \< 100 * preoperative international normalized ratio (inr) \> 1.1 * inappropriate cessation of anticoagulation medications prior to surgery * intolerance to hydromorphone or methadone * contraindication to administration of liposomal bupivacaine * subsequent surgeries after index surgery
proof-of-concept study of blood markers of tumor dissemination in patients with versus without intestinal polyps

Conditions: Colorectal Cancer; Neoplasm Metastasis; Disseminated Cancer

Summary: the study authors hypothesize that in patients with intestinal polyps, tumor cells could disseminate and circulating factors could be secreted by the polyp. these two parameters could become biomarkers to refine the follow-up of patients and to establish targeted therapeutic strategies.


Eligibility criteria:
inclusion criteria: * patient to be examined by colonoscopy * the patient must be a member or beneficiary of a health insurance plan exclusion criteria: * the subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study * the subject signals their opposition to participate in the study * it is impossible to give the subject informed information * the patient is under safeguard of justice or state guardianship * patient pregnant or breastfeeding * history of proven cancerous disease * patient followed for a chronic inflammatory bowel disease
validation of two acitivity monitors in three inpatient populations.

Conditions: Hip Fractures; Abdominal Surgery; Medical Patients

Summary: the aim of this study is to investigate the validity of sens motion and activpal acitivity monitors. thirthy-six patients from three different patient populations will be included: 12 acute high-risk abdominal surgery patients (+18 years), 12 hip fracture patients (+65) and 12 older medical patients (+65). each patient will be asked to wear two sets of activity monitors while performing a predefined researcher-supervised protocol consisting of a range of positions and activities including lying down, sitting, standing and walking. observations measured by time in each position will be used as a golden standard for physical activity and thus compared with the data produced by the acitivity monitors.

the study will investigate the association between activity measured by sens motion and activpal acitivity monitors, respectively, and direct observation in order to investigate to which degree the two types of activity monitors are able to classify activity (i.e. lying, sitting, standing, walking, up/down transitions and steps). thirty-six patients from three different patient populations will be included: 12 acute high-risk abdominal surgery patients (+18 years), 12 hip fracture patients (+65) and 12 older medical patients (+65). inclusion criteria to be fullfilled: 1) admission from own home. patients will be excluded for the following reasons: inability to walk independently with or without a walking aid; inability to transfer from lying to sitting, inability to transfer from sitting to standing, inability to cooperate, and inability to speak or understand danish. each patient will be asked to wear two sets of activity monitors (on the right thigh and on the chest) while performing a predefined, supervised protocol consisting of a range of positions and activities including lying down, sitting, standing and walking.

Eligibility criteria:
inclusion criteria: * older medical patient (+65) * older hip fracture patient (+65) * acute high-risk abdominal surgery patient (+18) * admitted from own home exclusion criteria: * inability to walk independently with or without a walking aid * inability to transfer from lying to sitting and sitting to standing * inability to cooperate * inability to understand or speak danish.

Keywords: validility activity moitoring
combination of radiotherapy and shr-1210 to treat patients with escc

Conditions: Esophageal Cancer

Summary: shr-1210 is a humanized anti-pd1 igg4 monoclonal antibody. this is an open-label，single center ，non-randomized ，single arm exploratory study . this clinical study is an investigator-initiatedclini-cal trial（iit ）.the objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-pd-1 antibody shr-1210 in patients with locally advanced esophageal squamous cell carcinomas。


Eligibility criteria:
inclusion criteria: 1. age:18-75 years, male or femal. 2. histologically confirmed primary squamous cell carcinoma of the esophagus,local advanced esophageal cancer diagnosed by pathology and imaging,clinical stage t3-4n0m0, t1-4n+m0,ⅱ-ⅳa. 3. pre-treatment evaluation can not tolerate concurrent radiochemotherapy or rejection of the concurrent use of chemotherapy with radiotherapy. 4. measurable disease based on response evaluation criteria in solid tumors (recist) 1.1. 5. ecog 0-1. 6. adequate organ function. 7. life expectancy of greater than 6 months. 8. patient has given written informed consent. exclusion criteria: 1. patients who have or are currently undergoing additional chemotherapy, radiation therapy, targeted therapy or immunotherapy. 2. known history of hypersensitivity to macromolecular protein preparation or any components of the shr- 1210 formulation. 3. subjects before or at the same time with other malignant tumors (except which has cured skin basal cell carcinoma and cervical carcinoma in situ); 4. subjects with any active autoimmune disease or history of autoimmune disease 5. uncontrolled clinically significant heart disease, including but not limited to the following: (1) \> nyha ii congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention; 6. active infection or an unexplained fever \> 38.5°c during screening or before the first scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion of the investigator); 7. received a live vaccine within 4 weeks of the first dose of study medication. 8. pregnancy or breast feeding. 9. decision of unsuitableness by principal investigator or physician-in-charge.
ultrasonographic and mri explorations of infraspinatus muscle in postero-superior rotator cuff tear

Conditions: Rotator Cuff Tears

Summary: the project aims to evaluate the contribution of texture analysis on mri sections, and the technical feasibility, reproducibility, and clinical relevance of quantitative ultrasound and elastography to characterize the composition and volume of infraspinatus muscle in postero-superior rotator cuff tears. the perspectives are to optimize the imaging to allow a quantitative, objective and reproducible analysis of the muscle tissue and its characteristics.

the rotator cuff of the shoulder consists of 4 tendinomuscular units including the infraspinatus. this complex system fulfils a double role: stabilization/coaptation (raising the arm) and arm mobility (especially external rotation). rupture of rotator cuff tendons is frequent (\> 80% among chronic shoulder pain). they go with a decrease in muscle volume (amyotrophy) and irreversible fat infiltration. the treatment is medical and then surgical (if necessary). the degrees of atrophy and muscle infiltration (especially infraspinatus) are the criteria of choice for surgery. actually, they are assessed in mri according to the classification of fuchs; it is operator dependent, qualitative and poorly reproducible with a strong inter-observer variability. our team highlighted (2016) the possibility of using texture analysis software to objectively measure the proportion of fatty tissue on mri sections of the cuff rotator muscles. this work also showed the possibility of using mode b ultrasound for morphological imaging and shear wave elastography to estimate the elasticity of the infraspinatus. the project aims to evaluate the contribution of texture analysis on mri sections, and the technical feasibility, reproducibility, and clinical relevance of quantitative ultrasound and elastography to characterize the composition and volume of infraspinatus muscle in postero-superior rotator cuff tears. the perspectives are to optimize the imaging to allow a quantitative, objective and reproducible analysis of the muscle tissue and its characteristics.

Eligibility criteria:
inclusion criteria: * ≥ 35 years-old and ≤75 years-old * tendonous, transfixing, postero-superior, unilateral and symptomatic rotator cuff lesions * controlateral shoulder without symptom, without rotator cuff injuries, without medical ou surgical history * written informed consent * affiliation to a social security system exclusion criteria: * pregnant woman * patient under legal protection * contraindications to mri * traumatic or surgical or medical relevant history on shoulder * general or local disease affecting the skeletal striated muscle

Keywords: rotator cuff tears mri ultrasonographic explorations